I would not hazard a guess here but doubt plaque reduction is an endpoint. Below is a good summary of potential endpoints courtesy of Roche as a clinician oriented educational offering, covering cognitive, fluid based imaging, CSF-derived biomarkers and related PET and MRI assessments. The imaging done as part of the EMERGE and ENGAGE studies with aducanumab we’re looking for ARIA side effects related to plaque reduction treatment. My memory is that the Leronlimab investigator initiated AD trial had an imaging endpoint but I have no clue what it would be if my memory is accurate.

https://www.cuba.dialogoroche.com/content/dam...trials.pdf